X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs TORRENT PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD TORRENT PHARMA BIOCON LTD/
TORRENT PHARMA
 
P/E (TTM) x 83.8 29.6 282.8% View Chart
P/BV x 7.9 5.6 140.0% View Chart
Dividend Yield % 0.2 1.0 16.3%  

Financials

 BIOCON LTD   TORRENT PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
TORRENT PHARMA
Mar-17
BIOCON LTD/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1621,768 65.7%   
Low Rs4831,186 40.7%   
Sales per share (Unadj.) Rs194.6346.1 56.2%  
Earnings per share (Unadj.) Rs34.455.2 62.4%  
Cash flow per share (Unadj.) Rs48.373.3 65.8%  
Dividends per share (Unadj.) Rs1.0014.00 7.1%  
Dividend yield (eoy) %0.10.9 12.8%  
Book value per share (Unadj.) Rs241.9257.1 94.1%  
Shares outstanding (eoy) m200.00169.22 118.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.24.3 99.1%   
Avg P/E ratio x23.926.8 89.3%  
P/CF ratio (eoy) x17.020.1 84.6%  
Price / Book Value ratio x3.45.7 59.2%  
Dividend payout %2.925.4 11.5%   
Avg Mkt Cap Rs m164,440249,887 65.8%   
No. of employees `0009.211.8 78.4%   
Total wages/salary Rs m7,4709,934 75.2%   
Avg. sales/employee Rs Th4,213.94,971.5 84.8%   
Avg. wages/employee Rs Th809.0843.2 95.9%   
Avg. net profit/employee Rs Th745.2792.4 94.0%   
INCOME DATA
Net Sales Rs m38,91158,569 66.4%  
Other income Rs m1,5712,233 70.4%   
Total revenues Rs m40,48260,802 66.6%   
Gross profit Rs m9,79513,773 71.1%  
Depreciation Rs m2,7723,069 90.3%   
Interest Rs m2602,056 12.6%   
Profit before tax Rs m8,33410,881 76.6%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6161,545 104.6%   
Profit after tax Rs m6,8819,336 73.7%  
Gross profit margin %25.223.5 107.0%  
Effective tax rate %19.414.2 136.6%   
Net profit margin %17.715.9 110.9%  
BALANCE SHEET DATA
Current assets Rs m40,47753,841 75.2%   
Current liabilities Rs m16,78331,612 53.1%   
Net working cap to sales %60.938.0 160.4%  
Current ratio x2.41.7 141.6%  
Inventory Days Days6097 61.3%  
Debtors Days Days8384 98.9%  
Net fixed assets Rs m45,07342,079 107.1%   
Share capital Rs m1,000846 118.2%   
"Free" reserves Rs m47,37742,655 111.1%   
Net worth Rs m48,37743,501 111.2%   
Long term debt Rs m21,08222,408 94.1%   
Total assets Rs m93,942101,250 92.8%  
Interest coverage x33.16.3 525.2%   
Debt to equity ratio x0.40.5 84.6%  
Sales to assets ratio x0.40.6 71.6%   
Return on assets %7.611.3 67.6%  
Return on equity %14.221.5 66.3%  
Return on capital %12.619.6 64.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,98820,066 64.7%   
Fx outflow Rs m7,8995,304 148.9%   
Net fx Rs m5,08914,762 34.5%   
CASH FLOW
From Operations Rs m6,40010,127 63.2%  
From Investments Rs m-4,985-7,869 63.3%  
From Financial Activity Rs m-1,775-1,918 92.5%  
Net Cashflow Rs m-473212 -223.6%  

Share Holding

Indian Promoters % 40.4 71.5 56.5%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 7.0 119.7%  
FIIs % 10.7 12.6 84.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.8 226.1%  
Shareholders   109,995 26,511 414.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   AUROBINDO PHARMA  MERCK LTD  PLETHICO PHARMA  CIPLA  GSK PHARMA  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jan 24, 2018 09:21 AM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS